Retatrutide research peptideBest Seller
Weight Management

Retatrutide

Triple-receptor (GLP-1, GIP, glucagon) weight management research compound. Preloaded 40mg pen for once-weekly subcutaneous injection.

Purity

99%+

CAS Number

Status

In Stock

Dispatch

Same-Day (before 2pm)

Select Size

£199.99

Research verification required. All orders are reviewed before dispatch. You will receive an email confirmation and a WhatsApp or phone call within 60 minutes to verify your research purpose.

Third-Party CoA Included Free Delivery Over £75 Research Use Only

About Retatrutide

Retatrutide is an experimental, once-weekly injectable compound being studied for chronic weight management, type 2 diabetes, and potentially fatty liver disease. Known as a "triple G" agonist, it targets three receptors (GLP-1, GIP, and glucagon) to suppress appetite and increase energy expenditure. Retatrutide is currently in Phase 3 clinical trials and is not yet approved by regulators for public use. However, initial results have produced significant reductions in body weight and many other benefits. Retatrutide mimics three hormones (GIP, GLP-1, and glucagon) to increase satiety, slow digestion, and boost metabolism. During trials, subjects started the dosage at 2mg once per week, injecting into the stomach or thigh area and slowly increasing the dosage per week or even split dosing the product twice a week. Effective results in trials showed that those who benefitted with long-term weight loss then stepped down the dosage once reaching the desired weight.

Research Applications

Technical Specifications

Compound NameRetatrutide
CategoryWeight Management
CAS Number
Molecular Weight
Molecular Formula
Sequence
Purity≥99%+ (HPLC)
FormLyophilised powder
Storage2-8°C refrigerated. Do not freeze.
ReconstitutionPre-mixed aqueous solution — no reconstitution required

Certificate of Analysis

Every order of Retatrutide includes a batch-specific CoA with HPLC chromatogram, mass spectrometry data, and laboratory accreditation details.

View Sample CoA

Retatrutide — Frequently Asked Questions

What makes Retatrutide different from other weight management compounds?

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Most current compounds target only one or two of these receptors. This triple mechanism is designed to suppress appetite, slow digestion, and boost metabolism through three distinct pathways.

How is Retatrutide administered in research settings?

Retatrutide is delivered via a preloaded 40mg injection pen designed for once-weekly subcutaneous administration. In clinical trials, injection sites include the abdomen and thigh. The pen requires no reconstitution — it is ready to use.

What dosage protocols have been used in trials?

During Phase 3 trials, subjects commenced at 2mg once per week and gradually increased the dosage. Some trials involved split dosing twice per week. Subjects who achieved their target weight then stepped down the dosage for maintenance.

Retatrutide is supplied by Premio Peptides (BELL RED LIMITED) exclusively for in vitro laboratory research. It is not a licensed medicine, is not approved for human or veterinary use, and must not be administered to any living organism outside a formally approved research protocol. Purchasers assume full responsibility for compliance with applicable regulations.

Related Compounds

BPC-157 research peptide
Healing & Recovery

BPC-157

£199.99View →
TB-500 research peptide
Healing & Recovery

TB-500

£199.99View →
CJC-1295 No DAC research peptide
Growth Hormone

CJC-1295 No DAC

£199.99View →